Ackman: Delta Variant Won’t Stop a Roaring Economy

Recovery stocks are the place to be, says hedge fund chief, in contrast to his jeremiads of 2020.


Hedge fund big shot Bill Ackman had a glorious 2020, betting on the pandemic to wreak havoc. And now? He’s put his chips on the economy’s comeback, which he claims even the Delta variant of the coronavirus won’t derail.

The variant simply isn’t that potent a threat to the economy, the CEO of Pershing Square Capital Management told CNBC. “I hope what it does is that it motivates anyone who doesn’t have the vaccine to get the vaccine. I don’t think it’s going to change behavior to a great extent,” Ackman said. “You are going to see a massive, in my view, economic boom. We are going to have an extremely strong economy coming in the fall.”

US COVID-19 infections have doubled over the past month, topping a 16% global increase. Ackman contended the variant is less deadly than other strains, and the US could attain herd immunity quicker as more people recover from the virus’s latest version.

What does that mean for investments? Bond yields will move much higher in 2021’s second half, amid recovery from the pandemic, he predicted. Right now, the benchmark 10-year Treasury note’s yield sits at a low 1.18% yield, down from 1.74% at the end of March. And it dipped another 0.2 percentage point Monday. Ackman labeled that a buying opportunity. “Today’s move—I would borrow as much as you can in the long-term fixed rate on the basis of today’s rates,” he said.

Never miss a story — sign up for CIO newsletters to stay up-to-date on the latest institutional investment industry news.

Ackman opined: “Short rates I think are going to go up a lot faster than people think. Coming to the turn of the year, I think we are going to have meaningfully higher yields as people realize the economy is going to make a big recovery.” Of course, not everyone agrees with him. A Wall Street Journal survey of economists found they expect economic growth to start cooling, diminishing from a 9.1% annual level in the just-completed second quarter to 3.2% next year.

Certainly, if rates go up, bond prices slump. Hence, Ackman is going heavily into recovery stocks, such as those in lodging, restaurants, and retail. So his top holdings include Hilton, Chipotle, and Lowe’s. He recently bought more Domino’s Pizza shares, boosting his position a percentage point to 8.2% of his portfolio.

 His sunny view is a at odds with his dour assessment in March 2020, when he warned investors that “hell is coming.” He urged the White House to lock the country down to thwart the infection’s spread. Around that time, he made a bearish bet that snagged him a $2.6 billion profit: He wagered on credit default swaps, in a bet that investment-grade and high-yield indexes would tank. They obligingly did.

Related Stories:

Ackman Scored $2.6 Billion on Bond Bets as Markets Sank

Ackman, Griffin, Coleman Are Among Hedge Fund Bigwigs Who Cleaned Up in 2020

One Year Later: 5 Ways the Pandemic Has Changed Investing

Tags: , , , , , , , ,

CEO, CTO Accused of Misleading Investors on COVID-19 Test

Parallax Health Sciences and the two executives settled charges related to claims the company made about a coronavirus screening test.


The US Securities and Exchange Commission (SEC) has settled charges with Parallax Health Sciences and two of its executives for allegedly making misleading statements about a COVID-19 screening test the company claimed to be developing. 

According to the SEC’s complaint, which was filed in the US District Court for the Southern District of New York, Parallax issued several press releases in March and April of 2020 that falsely claimed its COVID-19 screening test would be “available soon” and that it had medical and personal protective equipment (PPE) for immediate sale.

However, the SEC alleges that Parallax’s insolvency prevented it from developing the screening test, and that the company’s own projections showed that it would have taken more than a year to develop the test even if it had the funds it claimed to have, which it did not. 

The complaint also alleges that Parallax never had the medical equipment or the PPE it claimed to have for sale not only because it didn’t have enough money to buy it, but because it didn’t have approval from the US Food and Drug Administration (FDA) to import and sell the equipment. 

Never miss a story — sign up for CIO newsletters to stay up-to-date on the latest institutional investment industry news.

Despite the lack of funds or regulatory approval, the SEC alleges that CEO Paul Arena drafted misleading press releases to artificially boost Parallax’s declining stock price. 

“We allege that Parallax misled investors that the company was positioned to capitalize on opportunities created by the COVID pandemic,” Paul Levenson, director of the SEC’s Boston Regional Office, said in a statement. “Such misinformation jeopardized investors at precisely the moment when investors were attempting to respond to the financial implications of a public health emergency.”

The complaint alleges Arena knew that Parallax did not have enough money to develop a COVID-19 screening test or to acquire PPE or medical equipment. It also says he knew that the company lacked the FDA registrations required to import and sell the equipment.

“However, he drafted the seven misleading press releases to boost Parallax’s declining stock price,” according to the complaint. “This plan was successful,” said the SEC, which alleges that during a four-week period beginning March 11, 2020, the daily closing price of Parallax’s common stock in the US was on average 20% higher than between January 1, 2020, and March 10, 2020, which was the day before Parallax issued the first allegedly misleading release.

The SEC alleges Parallax Chief Technology Officer (CTO) Nathaniel Bradley helped Arena draft two press releases and posted content on Parallax’s website that claimed the company had PPE and medical equipment for immediate sale. While the regulator doesn’t accuse Bradley of being in on the alleged scam, it said he failed to verify the accuracy the announcements the company was making.

“Although Bradley was unaware of Arena’s plan to artificially boost Parallax’s stock price,” said the complaint, “he publicized Parallax’s claims that it had PPE and medical equipment available for sale without verifying that Parallax had the requisite capital and the necessary FDA registrations in place to acquire and distribute the equipment.”

For example, in April 2020, Parallax issued a press release stating that it had received more than $10 million worth of telehealth and medical supply contracts. However, the SEC alleges that in reality Parallax only had approximately $245,000 in orders at the time.

“Parallax and Arena knew, or recklessly disregarded, that the other orders that the company claimed were merely requests for price quotations that had not been pursued by the requesting parties or orders that had been canceled,” said the complaint.

Without admitting or denying the SEC’s charges, Parallax, Arena, and Bradley consented to pay penalties of $100,000, $45,000, and $40,000, respectively. Arena also agreed to be barred from acting as a public company officer or director for five years, while Bradley agreed to be prohibited from participating in an offering of a penny stock for three years. The settlements are subject to court approval.  

Related Stories:

Fintech CEO Pleads Guilty to COVID Loan Fraud

CEO Charged in Rapid COVID-19 Test Scam

SEC Charges Biotech Head with Using Pandemic to Defraud Investors

Tags: , , , , , , ,

«